Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Early Coronary Atherosclerosis in Women With Previous Preeclampsia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Incidence of Sudden Cardiac Death in the European Union

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Contemporary Management of Severe Symptomatic Aortic Stenosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Does Subclinical Leaflet Thrombosis Impact the Durability of Bioprosthetic Aortic Valves?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Percutaneous left atrial appendage closure in a surgically ligated left atrial appendage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Microcirculatory Function in Nonhypertrophic and Hypertrophic Myocardium in Patients With Aortic Valve Stenosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Doff B McElhinney
  • Yulin Zhang
  • Jamil A Aboulhosn
  • Brian H Morray
  • Elżbieta Katarzyna Biernacka
  • Athar M Qureshi
  • Alejandro J Torres
  • Shabana Shahanavaz
  • Bryan H Goldstein
  • Allison K Cabalka
  • Holly Bauser-Heaton
  • Stanimir Georgiev
  • Felix Berger
  • Oscar Millan-Iturbe
  • Lynn F Peng
  • Aimee K Armstrong
  • Daniel S Levi
  • Aneta Fronczak-Jakubczyk
  • Lars Sondergaard
  • Jason H Anderson
  • Dietmar Schranz
  • Thomas K Jones
  • John P Cheatham
  • Stephan Schubert
  • Peter Ewert
Vis graf over relationer

BACKGROUND: Endocarditis has emerged as one of the most impactful adverse events after transcatheter pulmonary valve replacement (TPVR), but there is limited information about risk factors for and outcomes of this complication.

OBJECTIVES: The purpose of this study was to evaluate risk factors for and outcomes of endocarditis in a large multicenter cohort.

METHODS: The authors established an international registry focused on characterizing endocarditis after TPVR, including the incidence, risk factors, characteristics, and outcomes.

RESULTS: Investigators submitted data for 2,476 patients who underwent TPVR between July 2005 and March 2020 and were followed for 8,475 patient-years. In total, 182 patients were diagnosed with endocarditis a median of 2.7 years after TPVR, for a cumulative incidence of 9.5% (95% CI: 7.9%-11.1%) at 5 years and 16.9% (95% CI: 14.2%-19.8%) at 8 years (accounting for competing risks: death, heart transplant, and explant) and an annualized incidence of 2.2 per 100 patient-years. Staphylococcus aureus and Viridans group Streptococcus species together accounted for 56% of cases. Multivariable analysis confirmed that younger age, a previous history of endocarditis, and a higher residual gradient were risk factors for endocarditis, but transcatheter pulmonary valve type was not. Overall, right ventricular outflow tract (RVOT) reintervention was less often to treat endocarditis than for other reasons, but valve explant was more often caused by endocarditis. Endocarditis was severe in 44% of patients, and 12 patients (6.6%) died, nearly all of whom were infected with Staphylococcus aureus.

CONCLUSIONS: The incidence of endocarditis in this multicenter registry was constant over time and consistent with prior smaller studies. The findings of this study, along with ongoing efforts to understand and mitigate risk, will be critical to improve the lifetime management of patients with heart disease involving the RVOT. Although endocarditis can be a serious adverse outcome, TPVR remains an important tool in the management of RVOT dysfunction.

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind78
Udgave nummer6
Sider (fra-til)575-589
Antal sider15
ISSN0735-1097
DOI
StatusUdgivet - 10 aug. 2021

Bibliografisk note

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

ID: 72633306